Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician

References

• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
   PubMed Web of Science ®Google Scholar
• Yiend J, Paykel E, Merritt R, et al. Long term outcome of primary care depression. J Affect Disord 2009;118:79-96
   Google Scholar
• Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:851-8
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
   PubMed Web of Science ®Google Scholar
• Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry 2007;68(Suppl. 8):26-34
   PubMed Web of Science ®Google Scholar
• Stahl SM. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry 2002;63:382-3
   PubMed Web of Science ®Google Scholar
• Blier P. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci 2001;26(Suppl.):S3-10
   PubMedGoogle Scholar
• Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143:415-26
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Jhee S, Grothe D. Antidepressant drug–drug interaction profile update. Drugs R D 2005;6:323-36
   PubMedGoogle Scholar
• Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289-304
   PubMed Web of Science ®Google Scholar
• Viale G. An economic analysis of physician prescribing of selective serotonin reuptake inhibitors. Hosp Pharm 1998;33:847-50
   Google Scholar
• Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007;113:134-53
   PubMed Web of Science ®Google Scholar
• Pincus HA, Pettit AR. The societal costs of chronic major depression. J Clin Psychiatry 2001;62:5-9
   PubMed Web of Science ®Google Scholar
• Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, 2008
   Google Scholar
• Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company, 2007
   Google Scholar
• Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, 2008
   Google Scholar
• Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65
   PubMed Web of Science ®Google Scholar
• Effexor [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, 2004
   Google Scholar
• DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88
   PubMed Web of Science ®Google Scholar
• Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-47
   PubMed Web of Science ®Google Scholar
• Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-53
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877-90
   PubMed Web of Science ®Google Scholar
• Thase ME, Kornstein SG, Germain J-M, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009;14:144-54
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kornstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009;14:183-95
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC, 1994
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical Global Impressions. Publication ADM 76-338. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, 1976:217-22
   Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl. 20):22-33
   PubMed Web of Science ®Google Scholar
• World Health Organization. Wellbeing measures in primary health care/the depcare project. Copenhagen, Denmark: WHO Regional Office for Europe, 1998
   Google Scholar
• Kornstein SG, Thase ME, Tummala R, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. Poster presented at American Psychiatric Association Annual Meeting, 3–8 May 2008, Washington DC
   Google Scholar
• Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44:77-87
   PubMed Web of Science ®Google Scholar
• Tourian KA, Leurent C, Graepel J, et al. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry (in press)
   Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13
   PubMed Web of Science ®Google Scholar
• McElroy S, Sachse C, Brockmoller J, et al. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci 2000;2:E33
   PubMedGoogle Scholar
• Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug–drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos 2008;36:2484-91
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Nichols AI, Paul J, et al. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract 2008;14:368-78
   PubMed Web of Science ®Google Scholar
• Kane C, Nichols A, Focht K, et al. Assessing the pharmacokinetics of venlafaxine ER 75 mg and desvenlafaxine 50 mg in CYP2D6 extensive and poor metabolizers. Poster presented at New Clinical Drug Evaluation Unit Annual Meeting, 29 June – 2 July 2009, Hollywood, FL
   Google Scholar
• Preskorn SH, Flockhart D. 2004 Guide to psychiatric drug interactions. Prim Psychiatry 2004;11:39-60
   Google Scholar
• Weiss J, Dormann SM, Martin-Facklam M, et al. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003;305:197-204
   PubMed Web of Science ®Google Scholar
• Verschraagen M, Koks CH, Schellens JH, et al. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 1999;40:301-6
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Saito M, Sakai H, et al. Rapid characterization of drug–drug interaction in plasma protein binding using a surface plasmon resonance biosensor. Drug Metab Pharmacokinet 2008;23:120-7
   PubMed Web of Science ®Google Scholar
• Buxton ILO. Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action, and elimination. In: Bruton LL, Lazo JS, Parker KL (eds). Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill, 2006:1-42
   Google Scholar
• Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions?. Drug Saf 1995;12:227-33
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Khalil Q, Winiarska M, et al. Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio. JAMA 2006;295:1517-18
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Prakash A, Andorn AC, et al. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006;40:337-48
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63:424-34
   PubMed Web of Science ®Google Scholar
• Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999;60:22-8
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41
   PubMed Web of Science ®Google Scholar
• Gregorian RS, Golden KA, Bahce A, et al. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002;36:1577-89
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kornstein SG, Rosas G, et al. Pooled analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. Poster presented at American Psychiatric Association Annual Meeting, 3–8 May 2008, Washington, DC
   Google Scholar
• Howell SR, Husbands GE, Scatina JA, et al. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993;23:349-59
   PubMed Web of Science ®Google Scholar